Phosphate restriction in diet therapy

Contributions to Nephrology

Volumn 155, Issue , 2007, Pages 113-124

  Takeda, Eiji ^a   Yamamoto, Hironori ^a   Nishida, Yuka ^a   Sato, Tadatoshi ^a   Sawada, Naoki ^a   Taketani, Yutaka ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 33947599161     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000101004     Document Type: Review

References (43)

1. Takeda E, Taketani Y, Morita K, Tatsumi S, Kanako K, Nii T, Yamamoto H, Miyamoto K: Molecular Mechanisms of Mammalian Inorganic Phosphate Homeostasis; Advanced Enzyme Regulation. Great Britain, Elsevier Science, 2000, vol 40, pp 285-302.
2. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium X phosphorus product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:607-617.
3. Portale AM, Booth BE, Halloran BP, Morris RC: Effect of dietary phosphorus on circulating concentration of 1,25 dihydroxy vitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency. J Clin Invest 1984;73:1580-1589.
4. National Kidney Foundation: K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002;39(suppl 1):S1-S266.
5. Motock GT, Loghman-Adham M, Totzke MT, Westenfelder C: Normal adaptive response of renal and intestinal brush border membrane to low Pi diet in uremic rats. J Am Soc Nephrol 1991;2:627A.
6. Yamashita T, Yoshioka M, Itoh N: Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000;277:494-498.
7. Shimada T, Hasegawa H, Yamazaki Y, Muto T, Hino R, Takeuchi Y, Fujita T, Nakahara K, Fukumoto S, Yamashita T: FGF-23 is a potent regulator of the vitamin D metabolism and phosphate homeostasis. J Bone Miner Res 2004;19:429-435.
8. Larsson T, Nisbeth U, Ljunggren O, Juppner H, Jonsson KB: Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003;64:2272-2293.
9. Imanishi Y, Inaba M, Nakatsuka K, Nagasue K, Okuno S, Yoshihara A, Miura M, Miyauchi A, Kobayashi K, Miki T, Shoji T, Ishimura E, Nishizawa Y: FGF-23 in patients with end-stage renal disease on hemodialysis. Kidney Int 2004;65:1943-1946.
10. Nakanishi S, Kazama JJ, Nii-Kono T, Omori K, Yamashita T, Fukumoto S, Gejyo F, Shigematsu T, Fukagawa M: Serum fibroblast growth factor-23 levels predict the future refractory hyperparathyroidism in dialysis patients. Kidney Int 2005;67:1171-1178.
11. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM: Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004;15:2208-2218.
12. London GM, Pannier B, Marchais SJ, Guerin AP: Calcification of the aortic valve in the dialyzed patient. J Am Soc Nephrol 2000;11:778-783.
13. Blacher J, Guerin A, Pannier B, Marchais S, London G: Arterial calcifications, arterial stiffness, and cardiovascular risk in end-stage renal disease. Hypertension 2001;38:938-942.
14. Borle AB, Uchikawa T: Effect of parathyroid hormone on the distribution and transport of calcium in cultured kidney cells. Endocrinology 1978;102:1725-1732.
15. Laflamme GH, Jowsey J: Bone and soft tissue changes with oral phosphate supplements. J Clin Invest 1972;51:2834-2940.
16. Block GA, Hulbert-Shearon TE, Levin NW, Port FK: Association of serum phosphorus and calcium X phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am J Kidney Dis 1998;31:601-617.
17. 4 product, and parathyroid hormone with cardiac mortality risk in chronic hemodialysis patients. J Am Soc Nephrol 2001;12:2131-2138.
18. Kestenbaum B, Sampson JN, Rudser KD, Patterson DJ, Seliger SL, Young B, Sherrard DJ, Andress DL: Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005;16:520-528.
19. Martinez I, Saracho R, Montenegro J, Llach F: The importance of dietary calcium and phosphorus in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis 1997;29:496-502.
20. Maschio G, Oldrizzi L, Tessitore N, D'Angelo A, Valvo E, Lupo A, Loschiavo C, Fabris A, Gammaro L, Rugiu C, et al: Early dietary protein and phosphorus restriction is effective in delaying progression of chronic renal failure. Kidney Int 1983;24:S273-S277.
21. Barsotti G, Morelli E, Giannoni A, Guiducci A, Lupetti S, Givannetti S: Restricted phosphorus and nitrogen intake to slow the progression of chronic renal failure: a contolled trial. Kidney Int 1983;24:S278-S284.
22. Barsotti G, Giannoni A, Morelli E, Lazzeri M, Vlamis I, Baldi R, Giovannetti S: The decline of renal function slowed by very low phosphorus intake in chronic renal patients following a low nitrogen diet. Clin Nephrol 1984;21:54-59.
23. Ciardella F, Morelli E, Niosi F, Caprioli R, Baldi R, Cupisti A, Petronio G, Carbone C, Barsotti G: Effects of a low phosphorus, low nitrogen diet supplemented with essential amino acids and ketoanalogues on serum triglycerides of chronic uremic patients. Nephron 1986;42:196-199.
24. Gin H, Aparicio M, Potaux L, de Precigout V, Bouchet J-L, Aubertin J: Low protein and low phosphorus diet in patients with chronic renal failure: influence on glucose tolerance and tissue insulin sensitivity. Metabolism 1987;36:1080-1085.
25. McCrory WW, Gertnet JM, Bruke FM, Pimental CT, Nemery RL: Effect of dietary phosphate restriction in children with chronic renal failure. J Pediatr 1987;111:410-412.
26. Blumenkrantz MJ, Kopple JD, Moran JK, Coburn JW: Metabolic balance studies and dietary protein requirements in patients undergoing continuous ambulatory peritoneal dialysis. Kidney Int 1982;21:849-861.
27. Lafage MH, Combe C, Fournier A, Aparicio M: Ketodiet, physiological calcium intake and native vitamin D improve renal osteodystrophy. Kidney Int 1992;42:1217-1225.
28. Aparicio M, Combe C, Lafage MH, De Precigout V, Potaux L, Bouchet JA: In advanced renal failure, dietary phosphorus restriction reverses hyperparathyroidism independent of changes in the levels of calcitriol. Nephron 1992;63:122-123.
29. Cozzolino M, Dusso AS, Slatopolsky D: Role of calcium-phosphate product and bone-associated proteins on vascular calcification in renal failure. J Am Soc Nephrol 2001;12:2511-2516.
30. Ribeiro S, Ramos A, Brandao A, Rebelo JR, Guerra A, Resina C, Vila-Lobos A, Carvalho F, Remedio F, Ribeiro F: Cardiac valve calcification in hemodialysis patients: role of calcium-phosphate metabolism. Nephrol Dial Transplant 1998;13:2037-2040.
31. Narang R, Ridout D, Nonis C, Kooner JS: Serum calcium, phosphorus, and albumin levels in relation to angioplastic severity of coronary artery disease. Int J Cardiol 1997;60:73-79.
32. Hulting J: Mitral valve calcification as an index of left ventricular dysfunction in patients with end stage renal disease on peritoneal dialysis. Chest 1994;105:383-388.
33. Slatopolsky E, Berkoben M, Kelber J, Brown A, Delmez J: Effects of calcitriol and non-calcemic vitamin D analogs on secondary hyperparathyroidism. Kidney Int Suppl 1992;38:S43-S49.
34. Schoenfeld P, Henry R, Laird N, Roxe D: Assessment of nutritional status of the National Cooperative Dialysis Study population. Kidney Int 1983;23(suppl 13):S80-S88.
35. Lorenzo V, de Bonis E, Rufino M, Hernandez D, Rebollo SG, Rodriguez AP, Torres A: Caloric rather than protein deficiency predominates in stable chronic hemodialysis patients. Nephrol Dial Transplant 1995;10:1885-1889.
36. Ramirez JA, Emmett M, White MG, Fathi N, Santa Ana CA, Morawski SG, Fordtran JS: The absorption of dietary phosphorus and calcium in hemodialysis patients. Kidney Int 1986;30:753-759.
37. Delmez J, Slatopolsky E: Hyperphosphatemia: its consequences and treatment in patients with chronic renal failure. Am J Kidney Dis 1992;19:303-317.
38. Sheik MS, Maguire JA, Emmet M, Santa Ana CA, Nicar MJ, Schiller LR: Reduction of phosphorus diet absorption by phosphate binders. A theoretical, in vitro and in vivo study. I Clin Invest 1989;83:66-73.
39. Lim VSS, Flanigan MJ, Fangman J: Effect of hematocrit on solute removal during high efficiency hemodialysis. Kidney Int 1990;37:1557-1562.
40. Rocco MV, Easter L, Makoff R: Management of hyperphosphatemia with calcium based binders. Semin Dial 1999;12:195-201.
41. Slatopolsky E, Delmez JA: Pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 1994;23:229-236.
42. Koiwa F, Kazama JJ, Tokumoto A, Onoda N, Kato H, Okada T, Nii-Kono T, Fukagawa M, Shigematsu T; ROD21 Clinical Research Group: Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005;9:336-339.
43. Chertow GM, Burke SK, Raggi P: Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002;62:245-252.